- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Candel Therapeutics Inc (CADL)
The Candel Therapeutics share price today is 10.57, view NASDAQ CADL stock exchange data. Track the latest Candel Therapeutics share price with real-time updates on CADL stock performance including market cap, day range, 52-week range and dividend yield. Access CADL charts, earnings dates and analyst estimates to support your investment decisions.
10.57
-0.08(-0.78%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
10.50
10.90
52 wk Range
4.35
11.36
Earnings results expected in 7 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
10.5010.90
52 wk Range
4.3511.36
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
CADL Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
20.50
Upside
+93.95%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Neutral
Analyst Ratings
8 Buy
1 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 20.50
(+93.95% Upside)
Earnings
Latest Release
14-05-2026
EPS / Forecast
-0.14 / -0.34
Revenue / Forecast
-- / --
Compare CADL to Peers and Sector
Metrics to compare | CADL | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCADLPeersSector | |
|---|---|---|---|---|
P/E Ratio | −14.4x | −4.0x | −0.4x | |
PEG Ratio | −1.47 | 0.00 | 0.00 | |
Price/Book | 5.7x | 1.8x | 2.6x | |
Price / LTM Sales | - | 18.5x | 3.1x | |
Upside (Analyst Target) | 111.3% | 146.8% | 47.5% | |
Fair Value Upside | Unlock | −4.9% | 5.9% | Unlock |
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Candel Therapeutics (CADL) Share Price Today?
The Candel Therapeutics share price today is 10.57.
What is the current Candel Therapeutics (CADL) share price and day range?
As of 12-08-2026, the Candel Therapeutics share price is 10.57, with a previous close of 10.65. The share price has ranged from 10.50 to 10.90 today, while the 52-week range spans from 4.35 to 11.36.
What Is the Candel Therapeutics Market Cap?
As of today, Candel Therapeutics market cap is 773.73M.
What Is the Candel Therapeutics (CADL) Share Price Target?
The average 12-month share price target for Candel Therapeutics is 20.50, with a high estimate of 29 and a low estimate of 9. 8 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +93.95% Upside potential.
What Is Candel Therapeutics's Earnings Per Share (TTM)?
The Candel Therapeutics EPS (TTM) is -0.97.
When Is the Next Candel Therapeutics Earnings Date?
Candel Therapeutics will release its next earnings report on 19-08-2026.
From a Technical Analysis Perspective, Is CADL a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
What Stock Exchange Does Candel Therapeutics Trade On?
Candel Therapeutics is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Candel Therapeutics?
The stock symbol for Candel Therapeutics is "CADL."
How Many Times Has Candel Therapeutics Stock Split?
Candel Therapeutics has split 0 times.
How Many Employees Does Candel Therapeutics Have?
Candel Therapeutics has 55 employees.
What Is the CADL Premarket Price?
CADL's last pre-market stock price is 10.26. The pre-market share volume is 310.00, and the stock has changed by -0.39, or -3.66%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.